Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- Stock Picks For Healthy Returns
Nov 25, 2008 10:19 AM
- A Bullish Outlook for Generic Drugs After Election
Nov 03, 2008 11:57 PM
- 5 Forward-Looking Trends In Healthcare
Oct 02, 2008 02:08 PM
- Pros and Cons of Owning Mylan Inc
Sep 10, 2008 09:51 PM
- Bookkeeping: Initiating Millipore Position
Aug 15, 2008 02:46 PM
- Periodicals Wrap-Up for Friday, August 15th
Aug 15, 2008 09:50 AM
- Periodicals Wrap-Up for Tuesday, July 22nd
Jul 22, 2008 10:28 AM
- Watson Pharma Gets FDA OK For Oxybutynin Topical Gel
May 28, 2008 03:23 AM
- Sell Barr Pharma on Bleak Outlook
May 23, 2008 10:30 PM
- Watson Reports Postive Data For Investigational Products
May 21, 2008 09:41 AM
- Watson Pharmaceuticals Receives FDA Final Approval for Generic Wellbutrin XL(R) 150 mg
Nov 26, 2008 04:00 PM
- Watson Enters Into Agreement to Acquire Products Related to Teva's Proposed Acquisition of Barr
Nov 25, 2008 08:02 AM
- Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer
Nov 13, 2008 04:00 PM
- Watson to Present at the 2008 Annual Credit Suisse Health Care Conference
Nov 06, 2008 08:01 AM
- Watson Pharmaceuticals Reports Third Quarter 2008 Results
Oct 29, 2008 07:01 AM
- Watson Files Lawsuit Against Barr for OXYTROL Patent Infringement
Oct 24, 2008 08:30 AM
- Watson to Host Third Quarter 2008 Earnings Conference Call and Webcast
Oct 17, 2008 08:01 AM
- UPDATE: Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH)
Oct 09, 2008 08:31 AM
- Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH)
Oct 08, 2008 06:01 PM
- Watson Announces Positive Data for Its Investigational Oxybutynin Topical Gel for the Treatment of Overactive Bladder at SUNA's Annual Conference
Oct 08, 2008 08:31 AM
- Form 4 WATSON PHARMACEUTICALS For: Sep 01 Filed by: BOYER ANDREW S (10K)
Sep 03, 2008 03:55 PM
- Form 4 WATSON PHARMACEUTICALS For: Sep 01 Filed by: MUNRO GORDON (10K)
Sep 03, 2008 03:33 PM
- Form 4 WATSON PHARMACEUTICALS For: Sep 01 Filed by: HEIMERS EDWARD F JR (10K)
Sep 03, 2008 01:24 PM
- Form 4 WATSON PHARMACEUTICALS For: Sep 01 Filed by: MIRANDA DIANE F (10K)
Sep 03, 2008 01:15 PM
- Form 4 WATSON PHARMACEUTICALS For: Sep 01 Filed by: JOYCE R TODD (10K)
Sep 03, 2008 01:12 PM
- Form 4 WATSON PHARMACEUTICALS For: Sep 01 Filed by: BUCHEN DAVID A (10K)
Sep 03, 2008 01:08 PM
- Form 4 WATSON PHARMACEUTICALS For: Sep 01 Filed by: AMATO LYNNE (10K)
Sep 03, 2008 01:03 PM
- Form 4 WATSON PHARMACEUTICALS For: Sep 01 Filed by: HSIA DAVID C (10K)
Sep 03, 2008 12:59 PM
- Form 4 WATSON PHARMACEUTICALS For: Aug 12 Filed by: Carmichael Clare (10K)
Aug 13, 2008 06:56 PM
- Form 3 WATSON PHARMACEUTICALS For: Aug 12 Filed by: Carmichael Clare (10K)
Aug 13, 2008 06:52 PM
Analyst Ratings
|
|
Share Performance
|
Period
|
WPI
|
Compare to S&P
|
| YTD |
-12.49 %
|
43.37 %
|
| 4 Weeks |
-9.25 %
|
-1.90 %
|
| 12 Weeks |
-20.70 %
|
9.92 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -2.08 %
|
|
EPS Growth in Last Year: 42.42 %
|
|
Sales Growth in Last Quarter: 2.90 %
|
|
Sales Growth in Last Quarter: 7.73 %
|
|
|
